ERBB2 and breast carcinoma: To analyse the effect of trastuzumab on HER2-positive breast cancer cells, MTT viability assays were performed with trastuzumab for the HCC1954 and SKBR3 cell lines, and the IC50 results of the cells were determined as 0.3 and 0.2, respectively (Table 1).